Patrick M Sweeney & Associates Inc. Takes Position in Eli Lilly and Company (NYSE:LLY)

Patrick M Sweeney & Associates Inc. acquired a new position in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 2,897 shares of the company’s stock, valued at approximately $1,689,000. Eli Lilly and Company makes up 1.5% of Patrick M Sweeney & Associates Inc.’s portfolio, making the stock its 14th largest position.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Lipe & Dalton acquired a new position in Eli Lilly and Company during the fourth quarter worth $26,000. Thompson Investment Management Inc. bought a new position in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $27,000. Optiver Holding B.V. acquired a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $36,000. Family CFO Inc acquired a new position in Eli Lilly and Company during the third quarter valued at approximately $40,000. Finally, O Brien Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 70.5% in the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after purchasing an additional 31 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.4 %

NYSE LLY traded down $2.77 on Wednesday, reaching $775.00. The company had a trading volume of 2,010,704 shares, compared to its average volume of 3,076,360. The stock has a market cap of $736.56 billion, a price-to-earnings ratio of 114.24, a PEG ratio of 1.45 and a beta of 0.37. The stock’s 50 day moving average is $761.22 and its 200-day moving average is $674.88. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 52 week low of $419.80 and a 52 week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same period last year, the firm posted $1.62 earnings per share. Equities analysts predict that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be paid a dividend of $1.30 per share. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.67%. Eli Lilly and Company’s payout ratio is 76.58%.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. Citigroup boosted their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday, April 30th. Truist Financial raised their price target on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Morgan Stanley raised their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $757.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.